2010
DOI: 10.1177/1074248410371947
|View full text |Cite
|
Sign up to set email alerts
|

Atrial Fibrillation-The Final Frontier

Abstract: Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and represents a significant health care issue. The diagnosis and management of AF uses a significant proportion of the health care budget and is responsible for substantial morbidity and mortality. Restoration and maintenance of sinus rhythm is still an important treatment option for symptomatic AF. Anti-arrhythmic drugs (AADs) have had inconsistent results for the prevention of recurrent AF and have been hampered by significant adverse … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
6
0

Year Published

2012
2012
2023
2023

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 7 publications
(6 citation statements)
references
References 112 publications
0
6
0
Order By: Relevance
“…Although existing evidence does not show one approach to be clearly superior to the other [10][11][12][13][14][15], in AF patients with distressing symptoms and/or seriously compromised cardiac function, it is of particular interest that cardioversion be achieved rapidly [5][6][7][8]16], as delayed cardioversion may worsen AF-associated symptoms and promote structural remodeling of the atria [17]. While various cardioversion therapies exist, their limitations, including limited use in certain comorbid patients, drug-drug interactions, and slow cardioversion rates, highlight the need for new treatments that are safer, more effective, and more timely in action [6,[18][19][20][21][22][23][24][25][26][27][28].…”
Section: Introductionmentioning
confidence: 99%
“…Although existing evidence does not show one approach to be clearly superior to the other [10][11][12][13][14][15], in AF patients with distressing symptoms and/or seriously compromised cardiac function, it is of particular interest that cardioversion be achieved rapidly [5][6][7][8]16], as delayed cardioversion may worsen AF-associated symptoms and promote structural remodeling of the atria [17]. While various cardioversion therapies exist, their limitations, including limited use in certain comorbid patients, drug-drug interactions, and slow cardioversion rates, highlight the need for new treatments that are safer, more effective, and more timely in action [6,[18][19][20][21][22][23][24][25][26][27][28].…”
Section: Introductionmentioning
confidence: 99%
“…9 People with AF generally have multiple other chronic conditions, a lower quality of life, a higher incidence of complications (particularly stroke), a higher mortality rate, and greater health care costs than patients with other forms of cardiovascular disease. [10][11][12][13] Because such a large fraction of those with AF are older than age 65, CMS bears a large portion of the significant burden-in terms of both cost and health outcomes-for this population. For example, Medicare beneficiaries with AF are estimated to have higher rates of inpatient hospitalizations than those without AF.…”
mentioning
confidence: 99%
“…The hybrid approach of combining endocardial and epicardial ablation to the treatment of AF was then discussed 2005 by Bisleri et al [9] and subsequently introduced in 2007 by Pak et al [10]. However, it is only a recent trend toward the use of this approach to treating cardiac arrhythmias [11] that has been gaining popularity [12], especially for the treatment of persistent AF [13].…”
Section: Continuing Cardiology Educationmentioning
confidence: 99%
“…. However, it is only a recent trend toward the use of this approach to treating cardiac arrhythmias that has been gaining popularity , especially for the treatment of persistent AF .…”
Section: Introductionmentioning
confidence: 99%